1. Home
  2. News
  3. Imugene Ltd
  4. Dose escalates In Phase I Clinical Trial of New Oncolytic Vi
More Imugene Ltd news
Imugene LtdASX: IMU

Dose escalates In Phase I Clinical Trial of New Oncolytic Vi

Nov 11, 2022 at 12:25 AM EST · Issued by Imugene Ltd

Filed with ASX · Nov 11, 2022 at 12:25 AM EST · 3 pages · English

On 6ix: 6ix.com/news/dose-escalates-in-phase-i-clinical-trial-of-new-oncolytic-vi

Imugene Ltd on 6ix

Story so far

  • Imugene Dose Escalates in Phase I Clinical Trial of VAXINIASep 1, 2022
  • First patient dosed in Phase I clinical trial of CHECKvaccOct 20, 2021

Earlier from Imugene

  • Imugene onCARlytics with blinatumomab SITC presentationNov 10, 2022
  • Europe Patent granted for iNKT Cell Therapy PlatformNov 6, 2022
  • First patient dosed in VAXINIA intratumoral cohort 2Oct 30, 2022
  • Preclinical trial of ALA iNKT therapy and IMU onCARlyticsSep 26, 2022
  • First patient IV dosed in VAXINIA Phase 1 clinical trialSep 20, 2022

Later from Imugene

  • Imugene onCARlytics with Estrella ARTEMIS T Cells SITCNov 13, 2022
  • First Patient Dosed in VAXINIA Intravenous Cohort 2Dec 4, 2022
  • CHECKVacc Data Presented at the 2022 SABC SymposiumDec 8, 2022
  • Imugene Receives Vaxinia Ethics Approval in AustraliaJan 8, 2023
  • Imugene VAXINIA trial advances to Combination CohortFeb 1, 2023
All Imugene news releases↗

Follow Imugene into a list and get an email when it puts out news.

Follow Imugene
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer